Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Thomas Peter Almdal"'
Autor:
Anders Blædel Gottlieb Hansen, Marie Lønberg Hansen, Sanja Golubovic, Paul Bloch, Janne Kunchel Lorenzen, Thomas Peter Almdal, Mathias Ried-Larsen, Ida Kær Thorsen
Publikováno v:
Research Involvement and Engagement, Vol 9, Iss 1, Pp 1-13 (2023)
Abstract Background Increased levels of physical activity are associated with beneficial health effects for people with type 2 diabetes, cardiovascular disease and/or severe obesity; however, transforming knowledge about these effects into action is
Externí odkaz:
https://doaj.org/article/c92b47bef85a4d5486311e54a7f7ce82
Autor:
Dea Haagensen Kofod, Nicholas Carlson, Ellen Freese Ballegaard, Thomas Peter Almdal, Christian Torp-Pedersen, Gunnar Gislason, Jesper Hastrup Svendsen, Bo Feldt-Rasmussen, Mads Hornum
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-11 (2023)
Abstract Background Cardiovascular mortality and the impact of cardiac risk factors in advanced chronic kidney disease (CKD) remain poorly investigated. We examined the risk of cardiovascular mortality in patients with advanced CKD with and without d
Externí odkaz:
https://doaj.org/article/4f57d81f7c3e4c76a1cc1a0ec3eda751
Autor:
Jesper Hastrup Svendsen, Theis Lange, Kirsten Nørgaard, Morten Lindhardt, Mads Hornum, Bo Feldt-Rasmussen, Marianne Rix, Søren Zöga Diederichsen, Dea Haagensen Kofod, Tobias Bomholt, Mads Ørbæk Andersen, Ylian Liem, Kristine Lindhard, Henrik Post Hansen, Casper Rydahl, Kristine Schandorff, Thomas Peter Almdal
Publikováno v:
BMJ Open, Vol 13, Iss 10 (2023)
Introduction Patients receiving haemodialysis are at increased risk of arrhythmias and sudden cardiac death, but data on arrhythmia burden and the pathophysiology remain limited. Among potential risk factors, hypoglycaemia is proposed as a possible t
Externí odkaz:
https://doaj.org/article/d0e064a161f54a8da5bbdf4b26412ce9
Autor:
Bibi Uhre Nielsen, Inger Hee Mabuza Mathiesen, Rikke Møller, Rikke Krogh-Madsen, Terese Lea Katzenstein, Tacjana Pressler, James A. M. Shaw, Christian Ritz, Michael R. Rickels, Darko Stefanovski, Thomas Peter Almdal, Daniel Faurholt-Jepsen
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
AimsThe purpose of the study was to further elucidate the pathophysiology of cystic fibrosis (CF)-related diabetes (CFRD) and potential drivers of hypoglycaemia. Hence, we aimed to describe and compare beta cell function (insulin and proinsulin) and
Externí odkaz:
https://doaj.org/article/88132567683d426abc643eb60765c95a
Autor:
Carina Kirstine Klarskov, Helga Holm Schultz, Frederik Persson, Tomas Møller Christensen, Thomas Peter Almdal, Ole Snorgaard, Katrine Bagge Hansen, Ulrik Pedersen-Bjergaard, Peter Lommer Kristensen
Publikováno v:
BMC Endocrine Disorders, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background A well-known metabolic side effect from treatment with glucocorticoids is glucocorticoid-induced diabetes mellitus (GIDM). Guidelines on the management of GIDM in hospitalized patients (in the non-critical care setting), recommend
Externí odkaz:
https://doaj.org/article/f4fa110cf6384814932410277b52166e
Autor:
Dea Haagensen Kofod, Thomas Peter Almdal, Vibeke Rømming Sørensen, Bo Feldt‐Rasmussen, Mads Hornum
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 5, Iss 1, Pp n/a-n/a (2022)
Abstract Introduction This study examined the prevalence of microvascular and macrovascular complications in people receiving dialysis with and without diabetes and investigated independent risk factors for foot ulcers and lower‐extremity amputatio
Externí odkaz:
https://doaj.org/article/632cc5ef016c40bf90b78697734a46b6
Autor:
Bibi Uhre Nielsen, Daniel Faurholt-Jepsen, Peter Sandor Oturai, Tavs Qvist, Rikke Krogh-Madsen, Terese Lea Katzenstein, James Shaw, Christian Ritz, Tacjana Pressler, Thomas Peter Almdal, Inger Hee Mabuza Mathiesen
Publikováno v:
Clinical Medicine Insights: Endocrinology and Diabetes, Vol 14 (2021)
Background: A frequent comorbidity in cystic fibrosis (CF) is CF related diabetes (CFRD) caused by a gradual decline in insulin secretion. The reduction in the anabolic hormone, insulin, might explain the weight loss that precedes onset of CFRD. We i
Externí odkaz:
https://doaj.org/article/7976cdda55fa499b9029168e96d5175b
Autor:
Kanita Zubcevic, Merete Petersen, Flemming Winther Bach, Aksel Heinesen, Thomas Peter Enggaard, Thomas Peter Almdal, Jakob Vormstrup Holbech, Lene Vase, Troels Stahelin Jensen, Christian Stevns Hansen, Nanna Brix Finnerup, Søren H. Sindrup
Publikováno v:
Zubcevic, K, Petersen, M, Bach, F W, Heinesen, A, Enggaard, T P, Almdal, T P, Holbech, J V, Vase, L, Jensen, T S, Hansen, C S, Finnerup, N B & Sindrup, S H 2023, ' Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment ', European Journal of Pain, vol. 27, no. 4, pp. 492-506 . https://doi.org/10.1002/ejp.2072
Zubcevic, K, Petersen, M, Bach, F W, Heinesen, A, Enggaard, T P, Almdal, T P, Holbech, J V, Vase, L, Jensen, T S, Hansen, C S, Finnerup, N B & Sindrup, S H 2023, ' Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment ', European Journal of Pain (United Kingdom), vol. 27, no. 4, pp. 492-506 . https://doi.org/10.1002/ejp.2072
Zubcevic, K, Petersen, M, Bach, F W, Heinesen, A, Enggaard, T P, Almdal, T P, Holbech, J V, Vase, L, Jensen, T S, Hansen, C S, Finnerup, N B & Sindrup, S H 2023, ' Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment ', European Journal of Pain (United Kingdom), vol. 27, no. 4, pp. 492-506 . https://doi.org/10.1002/ejp.2072
Background: Cannabinoids are often prescribed for neuropathic pain, but the evidence-based recommendation is ‘weak against’. Objectives: The aim was to examine the effect of two cannabinoids and their combination in peripheral neuropathic pain. M
Autor:
Therese Adrian, Mads Hornum, Filip K. Knop, Thomas Peter Almdal, Peter Rossing, Lisa Lida, Niels Søndergaard Heinrich, Vincent Boer, Anouk Marsman, Esben Petersen, Hartwig Siebner, Bo Feldt-Rasmussen
Publikováno v:
Nephrology Dialysis Transplantation. 37
BACKGROUND AND AIMS Non-alcoholic fatty liver disease (NAFLD) is suggested as being a risk factor for chronic kidney disease (CKD). The incidence of NAFLD is rising globally parallel to the increasing incidences of obesity and type 2 diabetes. As dia
Autor:
Dea Kofod, Nicholas Carlson, Ellen Linnea Freese Ballegaard, Christian Torp, Gunnar Gislason, Thomas Peter Almdal, Bo Feldt-Rasmussen, Mads Hornum
Publikováno v:
Nephrology Dialysis Transplantation. 37
BACKGROUND AND AIMS Chronic kidney disease (CKD) and diabetes are both well-established risk factors for cardiovascular mortality. However, the risk of cardiovascular mortality and the impact of diabetes for those who have already reached advanced CK